Modafinil is a medication that is primarily used to treat narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. However, it has also been shown to improve cognitive function in healthy individuals.
Modafinil works by increasing the levels of several neurotransmitters in the brain, including dopamine, norepinephrine, and histamine. Dopamine is a neurotransmitter that plays a role in motivation, attention, and decision-making. Norepinephrine is a neurotransmitter that plays a role in arousal and attention. Histamine is a neurotransmitter that plays a role in wakefulness. By increasing the levels of these neurotransmitters, modafinil can improve attention, focus, and alertness.
Additionally, modafinil has been shown to increase the activity of certain brain regions, such as the anterior cingulate cortex, which is involved in attention and decision-making. It also been shown to increase the activity of the hypothalamic orexin system, which is a key regulator of the sleep-wake cycle and plays an important role in maintaining wakefulness.
Modafinil has also been shown to improve working memory, which is the ability to hold and manipulate information in the mind in order to perform cognitive tasks. Studies have shown that modafinil can improve the ability to retain and process information, and may also improve the ability to multitask.
Modafinil also has been shown to improve executive function which is the ability to plan, organize, and complete tasks, as well as the ability to inhibit inappropriate responses. Studies have shown that modafinil can improve the ability to complete complex tasks and make decisions, as well as the ability to shift attention between different tasks.
It is important to note that modafinil is a prescription medication and should only be used under the guidance of a healthcare professional. Additionally, long-term effects of modafinil on cognitive function are not fully understood and more research is needed to fully understand its potential effects.
In sum, modafinil improves cognitive function by increasing the levels of several neurotransmitters, including dopamine, norepinephrine, and histamine, which improves attention, focus, and alertness. Additionally, modafinil increases the activity of certain brain regions, such as the anterior cingulate cortex and hypothalamic orexin system, which plays an important role in maintaining wakefulness. It also improves working memory and executive function, helping to retain and process information and to complete complex tasks and make decisions. However, modafinil is a prescription medication and should only be used under the guidance of a healthcare professional and the long-term effects of modafinil on cognitive function are not fully understood.
Mignot EJ (October 2012). "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics. 9 (4): 739–752. doi:10.1007/s13311-012-0150-9. PMC 3480574. PMID 23065655. Because of the relatively low risk of addiction, modafinil can be more easily prescribed in patients without a clear, biochemically defined central hypersomnia syndrome, and is also easier to stop, if needed. It is also a schedule IV compound.
^ Krishnan R, Chary KV (2015). "A rare case modafinil dependence". Journal of Pharmacology & Pharmacotherapeutics. J Pharmacol Pharmacotherapy. 6 (1): 49–50. doi:10.4103/0976-500X.149149. PMC 4319252. PMID 25709356.
^ Jump up to:a b c d e "Modafinil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved June 24, 2018.
^ "Modafinil Product information". Health Canada. April 25, 2012. Retrieved June 10, 2022.
^ "Provigil- modafinil tablet". DailyMed. November 30, 2018. Retrieved June 10, 2022.
^ "Nuvigil- armodafinil tablet". DailyMed. November 30, 2018. Retrieved June 10, 2022.
^ Jump up to:a b c d e Robertson P, Hellriegel ET (2003). "Clinical pharmacokinetic profile of modafinil". Clinical Pharmacokinetics. 42 (2): 123–137. doi:10.2165/00003088-200342020-00002. PMID 12537513. S2CID 1266677.
^ Jump up to:a b Robertson P, DeCory HH, Madan A, Parkinson A (June 2000). "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil". Drug Metabolism and Disposition. 28 (6): 664–671. PMID 10820139.
^ Jump up to:a b c d e f "Provigil Prescribing Information" (PDF). United States Food and Drug Administration. Teva Pharmaceuticals USA, Inc. January 2015. Retrieved July 18, 2015.
^ Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: potential clinical uses and mechanisms of action". Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/JCP.v67n0406. PMID 16669720.
^ Jump up to:a b Kredlow MA, Keshishian A, Oppenheimer S, Otto MW (2019). "The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 39 (5): 455–461. doi:10.1097/JCP.0000000000001085. PMID 31433334. S2CID 201119084.
^ Jump up to:a b c Battleday RM, Brem AK (November 2015). "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review". European Neuropsychopharmacology. 25 (11): 1865–1881. doi:10.1016/j.euroneuro.2015.07.028. PMID 26381811. S2CID 23319688.
^ Meulen R, Hall W, Mohammed A (2017). Rethinking Cognitive Enhancement. Oxford University Press. p. 116. ISBN 9780198727392.
^ Jump up to:a b c d BNF 74 (74 ed.). Pharmaceutical Press. September 2017. p. 468. ISBN 978-0857112989.
^ Jump up to:a b c Denis F (2021). "Smart drugs et nootropiques". Socio-anthropologie (43): 97–110. doi:10.4000/socio-anthropologie.8393. ISSN 1276-8707. S2CID 237863162.
^ Oberhaus D (November 30, 2016). "Why Can't We All Take Modafinil?". Vice. Vice Media. Archived from the original on November 12, 2020. Retrieved March 18, 2021.
^ "Modafinil - Drug Usage Statistics". ClinCalc. Retrieved October 16, 2021.
^ Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, et al. (November 2007). "Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report". Sleep. 30 (11): 1445–1459. doi:10.1093/sleep/30.11.1445. PMC 2082098. PMID 18041479.
^ Zee PC, Attarian H, Videnovic A (February 2013). "Circadian rhythm abnormalities". Continuum. 19 (1 Sleep Disorders): 132–147. doi:10.1212/01.CON.0000427209.21177.aa. PMC 3654533. PMID 23385698.
^ European Medicines Agency January 27, 2011 Questions and answers on the review of medicines containing Modafinil
^ "Overview | Multiple sclerosis in adults: Management | Guidance |". The National Institute for Health and Care Excellence (NICE). June 22, 2022.
^ "Provigil". National Multiple Sclerosis Society. Retrieved September 6, 2022.
^ "Les cobayes de la guerre du Golfe". Le Monde.fr. December 18, 2005.
^ Martin R (November 1, 2003). "It's Wake-Up Time". Wired. ISSN 1059-1028. Retrieved May 23, 2019.
^ Wheeler B (October 26, 2006). "BBC report on MoD research into modafinil". BBC News. Retrieved July 4, 2012.
^ "MoD's secret pep pill to keep forces awake". The Scotsman. February 27, 2005. Archived from the original on January 1, 2014. Retrieved December 31, 2013.
^ "Pilot pill project". News – City. PuneMirror. February 16, 2011. Archived from the original on March 19, 2012. Retrieved July 4, 2012.
^ Taylor Jr GP, Keys RE (December 1, 2003). "Modafinil and management of aircrew fatigue" (PDF). United States Department of the Air Force. Archived from the original (PDF) on June 12, 2009. Retrieved September 18, 2009.
^ "Air Force Special Operations Command Instruction 48–101" (PDF). November 30, 2012. Archived from the original (PDF) on April 10, 2018. (sects. 1.7.4), U.S. Air Force Special Operations Command
^ Thirsk R, Kuipers A, Mukai C, Williams D (June 2009). "The space-flight environment: the International Space Station and beyond". CMAJ. 180 (12): 1216–1220. doi:10.1503/cmaj.081125. PMC 2691437. PMID 19487390.
^ "Super Soldiers? Military Drug New Rage". ABC News. December 7, 2008.
^ "Like It or Not, "Smart Drugs" Are Coming to the Office". Harvard Business Review. May 2015.
^ Cadwalladr C (February 14, 2015). "Students used to take drugs to get high. Now they take them to get higher grades". The Guardian.
^ Talbot M. "Brain Gain". The New Yorker. Retrieved April 9, 2017.
^ Plotz D (August 21, 2003). "Medikamente: 100 Milligramm Arbeitswut". Die Zeit. Retrieved April 9, 2017.
^ van Rooyen, L.-R.; Gihwala, R.; Laher, A. E. (June 2021). "Stimulant use among prehospital emergency care personnel in Gauteng Province, South Africa". SAMJ: South African Medical Journal. 111 (6): 587–590. doi:10.7196/SAMJ.2021.v111i6.15465. ISSN 0256-9574.
^ "Professors are taking the same 'smart drugs' as students to keep up with workloads". The Independent. May 30, 2017. Retrieved January 17, 2023.
^ Jump up to:a b Schmitt KC, Reith ME (October 17, 2011). "The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors". PLOS ONE. 6 (10): e25790. Bibcode:2011PLoSO...625790S. doi:10.1371/journal.pone.0025790. PMC 3197159. PMID 22043293.
^ Jump up to:a b O'Brien CP (September 2012). "Modafinil-cocaine interactions: clinical implications". Biological Psychiatry. 72 (5): 346. doi:10.1016/j.biopsych.2012.07.004. PMID 22872012. S2CID 39238847.
^ Avelar AJ, Cao J, Newman AH, Beckstead MJ (September 2017). "Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons". Neuropharmacology. 123: 410–419. doi:10.1016/j.neuropharm.2017.06.016. PMC 5546153. PMID 28625719.
^ Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, et al. (August 2020). "Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions". Neuropsychopharmacology. 45 (9): 1518–1526. doi:10.1038/s41386-020-0680-5. PMC 7360549. PMID 32340023.
^ Dürsteler, Kenneth M; Berger, Eva-Maria; Strasser, Johannes; Caflisch, Carlo; Mutschler, Jochen; Herdener, Marcus; Vogel, Marc (December 31, 2015). "Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence". Substance Abuse and Rehabilitation. 6: 61–74. doi:10.2147/SAR.S50807. PMC 4476488. PMID 26124696.
^ Billiard M, Lubin S (2015). "Modafinil: Development and Use of the Compound". Sleep Medicine. New York, NY: Springer New York. pp. 541–544. doi:10.1007/978-1-4939-2089-1_61. ISBN 978-1-4939-2088-4.
^ Nasr S, Wendt B, Steiner K (October 2006). "Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice". Journal of Affective Disorders. 95 (1–3): 111–114. doi:10.1016/j.jad.2006.01.010. PMID 16737742.
^ Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C (July 2000). "Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy". Sleep Medicine. 1 (3): 231–243. doi:10.1016/s1389-9457(00)00031-9. PMID 10828434.
^ "Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group". Annals of Neurology. 43 (1): 88–97. January 1998. doi:10.1002/ana.410430115. PMID 9450772. S2CID 9526780.
^ "FDA data on Modafinil" (PDF). Accessdata.fda.gov. 2010. Retrieved September 9, 2018.
^ "FDA Provigil Drug Safety Data" (PDF). Fda.gov. January 2015.
^ Sousa A, Dinis-Oliveira RJ (2020). "Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects". Substance Abuse. 41 (2): 155–173. doi:10.1080/08897077.2019.1700584. PMID 31951804. S2CID 210709160.
^ Rugino T (June 2007). "A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents". Neuropsychiatric Disease and Treatment. 3 (3): 293–301. PMC 2654790. PMID 19300563.
^ Greenblatt K, Adams N (February 2022). "Modafinil". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30285371.
^ "Australian Adverse Drug Reactions Bulletin 2008" (etext). Australian Adverse Drug Reactions Bulletin. December 1, 2008. Retrieved November 29, 2017.
^ "Provigil" (PDF). Medication Guide. Cephalon, Inc. November 1, 2010. Archived from the original (PDF) on March 4, 2016. Retrieved December 31, 2013.
^ Jump up to:a b c d Kumar R (2008). "Approved and investigational uses of modafinil : an evidence-based review". Drugs. 68 (13): 1803–1839. doi:10.2165/00003495-200868130-00003. PMID 18729534. S2CID 38542387.
^ "Modafinil (marketed as Provigil): Serious Skin Reactions". Food and Drug Administration. 2007. Archived from the original on January 15, 2009. Retrieved December 16, 2019.
^ Banerjee D, Vitiello MV, Grunstein RR (October 2004). "Pharmacotherapy for excessive daytime sleepiness". Sleep Medicine Reviews. 8 (5): 339–354. doi:10.1016/j.smrv.2004.03.002. PMID 15336235.
^ Ivanenko A, Kek L, Grosrenaud J (April 28, 2017). "0954 Long-Term Use of Modafinil and Armodafinil in Pediatric Patients with Narcolepsy". Sleep. 40 (suppl_1): A354–A355. doi:10.1093/sleepj/zsx050.953. ISSN 0161-8105.
^ Jump up to:a b "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved August 16, 2015.
^ Kim D (February 22, 2012). "Practical use and risk of modafinil, a novel waking drug". Environmental Health and Toxicology. 27: e2012007. doi:10.5620/eht.2012.27.e2012007. PMC 3286657. PMID 22375280.
^ Warot D, Corruble E, Payan C, Weil JS, Puech AJ (1993). "Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo". European Psychiatry. 8 (4): 201–208. doi:10.1017/S0924933800002923. ISSN 0924-9338. S2CID 151797528.
^ O'Brien CP, Dackis CA, Kampman K (June 2006). "Does modafinil produce euphoria?". The American Journal of Psychiatry. 163 (6): 1109. doi:10.1176/ajp.2006.163.6.1109. PMID 16741217.
^ Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: Potential clinical uses and mechanisms of action" (PDF). The Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/jcp.v67n0406. PMID 16669720. S2CID 17047074. Archived from the original (PDF) on February 20, 2019.
^ International Narcotics Control Board (July 2020), Yellow List: List of Narcotic Drugs Under International Control, In accordance with the Single Convention on Narcotic Drugs, 1961 [Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961] (59th ed.), Yellow List PDF
^ International Narcotics Control Board (July 2020), Green List: List of Psychotropic Substances Under International Control, In accordance with Convention psychotropic substances of 1971 (31st ed.), United Nations Publications, Green List PDF
^ Jump up to:a b Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S (August 2017). "Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis". Substance Use & Misuse. 52 (10): 1292–1306. doi:10.1080/10826084.2016.1276597. PMID 28350194. S2CID 4775658.
^ "Modafinil drug interactions". Drugs.com. Retrieved May 3, 2021.
^ "MedlinePlus Drug Information: Modafinil". NIH. July 1, 2005. Archived from the original on June 10, 2007. Retrieved July 21, 2007.
^ Minzenberg MJ, Carter CS (June 2008). "Modafinil: a review of neurochemical actions and effects on cognition". Neuropsychopharmacology. Springer Science and Business Media LLC. 33 (7): 1477–1502. doi:10.1038/sj.npp.1301534. PMID 17712350. S2CID 13752498.
^ Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM (November 2006). "Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers". Journal of Psychopharmacology. SAGE Publications. 20 (6): 756–770. doi:10.1177/0269881106060770. PMID 16401653. S2CID 8033437.
^ Niwa T, Murayama N, Imagawa Y, Yamazaki H (May 2015). "Regioselective hydroxylation of steroid hormones by human cytochromes P450". Drug Metabolism Reviews. Informa UK Limited. 47 (2): 89–110. doi:10.3109/03602532.2015.1011658. PMID 25678418. S2CID 5791536.
^ Aquinos BM, García Arabehety J, Canteros TM, de Miguel V, Scibona P, Fainstein-Day P (2021). "[Adrenal crisis associated with modafinil use]". Medicina (in Spanish). 81 (5): 846–849. PMID 34633961.
^ "Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers". FDA. May 26, 2021.
^ "Cytochrome P450 3A (including 3A4) inhibitors and inducers". UpToDate.
^ Jump up to:a b c d e f g h i j k l m n Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. (May 2009). "Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 738–746. doi:10.1124/jpet.108.146142. PMC 2672878. PMID 19197004.
^ Jump up to:a b c Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, et al. (October 2021). "Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol". Pharmacology Research & Perspectives. 9 (5): e00855. doi:10.1002/prp2.855. PMC 8381683. PMID 34423920.
^ Jump up to:a b c Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S (February 2018). "An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil". ACS Chemical Neuroscience. 9 (2): 151–158. doi:10.1021/acschemneuro.7b00374. PMID 29115823.
^ Jump up to:a b c d e Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, et al. (September 2012). "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse". Biological Psychiatry. 72 (5): 405–413. doi:10.1016/j.biopsych.2012.03.022. PMC 3413742. PMID 22537794.
^ Jump up to:a b c d Seeman P, Guan HC, Hirbec H (August 2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. PMID 19391150. S2CID 17758902.
^ Jump up to:a b Stahl SM (March 2017). "Modafinil". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp. 491–495. ISBN 9781108228749.
^ Jump up to:a b c Gerrard P, Malcolm R (June 2007). "Mechanisms of modafinil: A review of current research". Neuropsychiatric Disease and Treatment. 3 (3): 349–364. PMC 2654794. PMID 19300566.
^ Ishizuka T, Murotani T, Yamatodani A (2012). "Action of modafinil through histaminergic and orexinergic neurons". Sleep Hormones. Vitamins & Hormones. Vol. 89. pp. 259–78. doi:10.1016/B978-0-12-394623-2.00014-7. ISBN 9780123946232. PMID 22640618.
^ Jump up to:a b Salerno M, Villano I, Nicolosi D, Longhitano L, Loreto C, Lovino A, et al. (January 2019). "Modafinil and orexin system: interactions and medico-legal considerations". Frontiers in Bioscience. 24 (3): 564–575. doi:10.2741/4736. PMID 30468674. S2CID 53713777.
^ Jump up to:a b Ishizuka T, Murakami M, Yamatodani A (January 2008). "Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats". European Journal of Pharmacology. 578 (2–3): 209–215. doi:10.1016/j.ejphar.2007.09.009. PMID 17920581.
^ Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK (July 2007). "Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants". European Journal of Pharmacology. 568 (1–3): 112–123. doi:10.1016/j.ejphar.2007.03.044. PMID 17477916.
^ Murillo-Rodríguez E, Haro R, Palomero-Rivero M, Millán-Aldaco D, Drucker-Colín R (January 2007). "Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats". Behavioural Brain Research. 176 (2): 353–357. doi:10.1016/j.bbr.2006.10.016. PMID 17098298. S2CID 30192761.
^ de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S (November 2001). "Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats". NeuroReport. 12 (16): 3533–3537. doi:10.1097/00001756-200111160-00032. PMID 11733706. S2CID 31726815.
^ Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P (February 2004). "Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study". Sleep. 27 (1): 19–25. PMID 14998233.
^ Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T (April 2002). "Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression". Journal of Neuroscience Research. 68 (1): 107–112. doi:10.1002/jnr.10196. PMID 11933055. S2CID 43731660.
^ Jump up to:a b c Federici M, Latagliata EC, Rizzo FR, Ledonne A, Gu HH, Romigi A, et al. (November 2013). "Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation". Neuroscience. 252: 118–124. doi:10.1016/j.neuroscience.2013.07.071. PMID 23933217. S2CID 7588529.
^ Jump up to:a b c Okunola-Bakare OM, Cao J, Kopajtic T, Katz JL, Loland CJ, Shi L, Newman AH (February 2014). "Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues". Journal of Medicinal Chemistry. 57 (3): 1000–1013. doi:10.1021/jm401754x. PMC 3954497. PMID 24494745.
^ Young JW (March 2009). "Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness". The Journal of Neuroscience. 29 (9): 2663–2665. doi:10.1523/JNEUROSCI.5843-08.2009. PMC 2697968. PMID 19261860.
^ Jump up to:a b c Wisor J (October 2013). "Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions". Frontiers in Neurology. 4: 139. doi:10.3389/fneur.2013.00139. PMC 3791559. PMID 24109471.
^ Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H, Okubo Y (May 2014). "In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I". The International Journal of Neuropsychopharmacology. 17 (5): 697–703. doi:10.1017/S1461145713001612. PMID 24451483.
^ Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. (March 2009). "Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications". JAMA. 301 (11): 1148–1154. doi:10.1001/jama.2009.351. PMC 2696807. PMID 19293415.
^ Jump up to:a b c d Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
^ Jump up to:a b c d Quisenberry AJ, Baker LE (December 2015). "Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats". Psychopharmacology. 232 (24): 4411–4419. doi:10.1007/s00213-015-4065-0. PMID 26374456. S2CID 15519396.
^ Jump up to:a b c d e Mereu M, Bonci A, Newman AH, Tanda G (October 2013). "The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders". Psychopharmacology. 229 (3): 415–434. doi:10.1007/s00213-013-3232-4. PMC 3800148. PMID 23934211.
^ Jump up to:a b c Tanda G, Hersey M, Hempel B, Xi ZX, Newman AH (February 2021). "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Current Opinion in Pharmacology. 56: 13–21. doi:10.1016/j.coph.2020.07.007. PMC 8247144. PMID 32927246.
^ Stickgold R, Walker WP (May 22, 2010). The Neuroscience of Sleep. Academic Press. pp. 191–. ISBN 978-0-12-375722-7.
^ Jump up to:a b Simon P, Hémet C, Ramassamy C, Costentin J (December 1995). "Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice". European Neuropsychopharmacology. 5 (4): 509–514. doi:10.1016/0924-977x(95)00041-m. PMID 8998404.
^ Jump up to:a b Dunn D, Hostetler G, Iqbal M, Marcy VR, Lin YG, Jones B, et al. (June 2012). "Wake promoting agents: search for next generation modafinil, lessons learned: part III". Bioorganic & Medicinal Chemistry Letters. 22 (11): 3751–3753. doi:10.1016/j.bmcl.2012.04.031. PMID 22546675.
^ Jump up to:a b c Chatterjie N, Stables JP, Wang H, Alexander GJ (August 2004). "Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity". Neurochemical Research. 29 (8): 1481–1486. doi:10.1023/b:nere.0000029559.20581.1a. PMID 15260124. S2CID 956077.
^ Jump up to:a b c Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
^ Korotkova TM, Klyuch BP, Ponomarenko AA, Lin JS, Haas HL, Sergeeva OA (February 2007). "Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors". Neuropharmacology. 52 (2): 626–633. doi:10.1016/j.neuropharm.2006.09.005. PMID 17070873. S2CID 33713638.
^ Jump up to:a b Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, Sambataro F, et al. (September 2010). "Modulatory effects of modafinil on neural circuits regulating emotion and cognition". Neuropsychopharmacology. 35 (10): 2101–2109. doi:10.1038/npp.2010.83. PMC 3013347. PMID 20555311.
^ van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (May 2006). "Behavioral effects of modafinil in marmoset monkeys". Psychopharmacology. 185 (4): 433–440. doi:10.1007/s00213-006-0340-4. hdl:1874/19740. PMID 16550386. S2CID 12681062.
^ ePainAssist Team (March 20, 2018). "What Happens If Amygdala Is Damaged?". Epainassist. Retrieved August 24, 2022.
^ "APA PsycNet". psycnet.apa.org. Retrieved January 9, 2023.
^ Ellinwood EH, Sudilovsky A, Nelson LM (October 1973). "Evolving behavior in the clinical and experimental amphetamine (model) psychosis". The American Journal of Psychiatry. 130 (10): 1088–1093. doi:10.1176/ajp.130.10.1088. PMID 4353974.
^ Philmore R (March 8, 2013). "Effect of Modafinil at Steady State on the Single-Dose Pharmacokinetic Profile of Warfarin in Healthy Volunteers". The Journal of Clinical Pharmacology. 42 (12): 205–214. doi:10.1177/00912700222011120. PMID 11831544. S2CID 29223738.
^ Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS (January 2008). "Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein". European Journal of Pharmacology. 578 (2–3): 148–158. doi:10.1016/j.ejphar.2007.09.035. PMC 2659508. PMID 17963743.
^ Jump up to:a b Gilman A, Goodman LS, Hardman JG, Limbird LE (2001). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. p. 1984. ISBN 978-0-07-135469-1.
^ Jump up to:a b Schwertner HA, Kong SB (March 2005). "Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography". Journal of Pharmaceutical and Biomedical Analysis. 37 (3): 475–479. doi:10.1016/j.jpba.2004.11.014. PMID 15740906.
^ Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, et al. (October 1998). "Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology. 38 (10): 971–978. doi:10.1002/j.1552-4604.1998.tb04395.x. PMID 9807980. S2CID 32857213.
^ Robertson P, Hellriegel ET, Arora S, Nelson M (January 2002). "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers". Clinical Pharmacology and Therapeutics. 71 (1): 46–56. doi:10.1067/mcp.2002.121217. PMID 11823757. S2CID 21552865.
^ Vetrivelan R, Saper CB, Fuller PM (2014). "Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions". Nature and Science of Sleep. 6: 57–63. doi:10.2147/NSS.S53132. PMC 4014362. PMID 24833927.
^ Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE (March 1998). "Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology. 38 (3): 276–282. doi:10.1002/j.1552-4604.1998.tb04425.x. PMID 9549666. S2CID 26877375.
^ Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man. Foster City, CA: Biomedical Publications. pp. 1152–1153. ISBN 978-0-9626523-7-0.
^ Jump up to:a b Spratley TK, Hayes PA, Geer LC, Cooper SD, McKibben TD (2005). "Analytical Profiles for Five "Designer" Tryptamines" (PDF). Microgram Journal. 3 (1–2): 54–68.
^ Jump up to:a b "Modafinil reaction with the Froehde reagent and others". Reagent Tests UK. December 13, 2015. Retrieved December 18, 2015.
^ De Risi C, Ferraro L, Pollini GP, Tanganelli S, Valente F, Veronese AC (December 2008). "Efficient synthesis and biological evaluation of two modafinil analogues". Bioorganic & Medicinal Chemistry. 16 (23): 9904–9910. doi:10.1016/j.bmc.2008.10.027. PMID 18954992.
^ Napoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A (2020). "The Psychonauts' World of Cognitive Enhancers". Frontiers in Psychiatry. 11: 546796. doi:10.3389/fpsyt.2020.546796. PMC 7516264. PMID 33024436.
^ Ballas CA, Kim D, Baldassano CF, Hoeh N (July 2002). "Modafinil: past, present and future". Expert Review of Neurotherapeutics. 2 (4): 449–457. doi:10.1586/14737175.2.4.449. PMID 19810941. S2CID 32939239.
^ Healy M (May 2, 2013). "Use of wake-up drug modafinil takes off, spurred by untested uses – Los Angeles Times". LA Times. Retrieved December 31, 2013.
^ Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (February 21, 2012). Alessi-Severini S (ed.). "The prevalence and cost of unapproved uses of top-selling orphan drugs". PLOS ONE. 7 (2): e31894. Bibcode:2012PLoSO...731894K. doi:10.1371/journal.pone.0031894. PMC 3283698. PMID 22363762.
^ "Cephalon gets six-month Provigil patent extension". Philadelphia Business Journal. March 28, 2006. Retrieved July 21, 2007.
^ "Prescription Access Litigation (PAL) Project :: Prescription Access Litigation (PAL) Project :: Lawsuits & Settlements :: Current Lawsuits". Prescriptionaccess.org. Retrieved July 4, 2012.
^ "Document 514 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. Retrieved July 4, 2012.
^ Jump up to:a b "Document 513 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. Retrieved July 4, 2012.
^ "Cephalon Inc., SEC 10K 2008 disclosure". February 23, 2009. pp. 9–10. Retrieved August 29, 2009.
^ "CVS, Rite Aid Sue Cephalon Over Generic Provigil". Bloomberg News. August 21, 2009. Retrieved August 29, 2009.
^ "Canada IP Year in Review 2008". January 1, 2009.
^ "Shire v. Canada". Archived from the original on April 24, 2010. Retrieved August 29, 2009.
^ "Cephalon Sues Apotex". Zacks.com. August 20, 2010. Archived from the original on March 5, 2012. Retrieved July 4, 2012.
^ ""U.S. Federal Trade Commission Clears Teva's Acquisition of Cephalon". Business Wire. October 7, 2011. Archived from the original on April 18, 2016. Retrieved March 11, 2013. Teva will also grant non-exclusive U.S. rights to an undisclosed company to market modafinil tablets, the generic version of Provigil(R), which had annual brand sales in the U.S. of approximately $1.1 billion
^ "Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals". Press Release. PRNewswire. October 18, 2011. Retrieved July 4, 2012.
^ Larson E (November 19, 2010). "Cephalon Loses U.K. Bid to Halt Mylan, Orchid Generic-Drug Sales". bloomberg LP. Archived from the original on November 25, 2010. Retrieved January 28, 2019.
^ "Modafinil – International Brands". Drugs.com. Retrieved January 8, 2017.
^ "Poisons Standard March 2018". Legislation.gov.au. Retrieved January 20, 2019.
^ "Regulations Amending the Food and Drug Regulations (1184 — Modafinil)". Canada Gazette. 140 (20). March 26, 2005. Archived from the original on July 6, 2011.
^ "食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知". China Food and Drug Administration. Archived from the original on December 5, 2018. Retrieved November 11, 2013.
^ "处方管理办法（原卫生部令第53号）". 中国政府网 (in Chinese).
^ "莫达非尼国内获批上市 威尔曼新药拥有量再上台阶". people.cn (in Chinese). December 18, 2017.[permanent dead link]
^ "List of psychotropics" (PDF). Archived from the original (PDF) on July 11, 2019. Retrieved May 24, 2019.
^ "モダフィニルの向精神薬への指定". Archived from the original on May 15, 2015. Retrieved January 17, 2017.
^ "医疗用医薬品の添付文书情报-モディオダール锭１００ｍｇ". 独立行政法人 医薬品医疗机器総合机构 (in Japanese). Archived from the original on February 9, 2019. Retrieved February 9, 2019.
^ "モダフィニル密輸で逮捕された歯科医師，ダイエットに使用と供述（報道）". Medicallaw.exblog.jp. Archived from the original on January 21, 2019. Retrieved January 20, 2019.
^ "向精神薬をインドから密輸入した男を逮捕". Hayabusa3.5ch.net. Retrieved January 20, 2019.
^ "AGENȚIA NAȚIONALĂ ANTI-DOPING" (PDF). Archived from the original (PDF) on February 24, 2021. Retrieved January 21, 2019.
^ "Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" (PDF). Archived from the original (PDF) on August 7, 2019. Retrieved August 7, 2019.
^ "Is It Illegal to Obtain Controlled Substances From the Internet?". United States Drug Enforcement Administration. Archived from the original on July 9, 2007. Retrieved July 21, 2007.
^ U.S. Justice Department (January 27, 1999). "Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV". Federal Register: The Daily Journal of the United States Government. A Rule by the Justice Department on 01/27/1999. 64 FR 4050.
^ "USC 201 Section 1301.26 Exemptions from import or export requirements for personal medical use". United States Department of Justice. March 24, 1997. Archived from the original on February 3, 2007. Retrieved January 10, 2007.
^ "Prescription Drug Marketing Act of 1987 (PDMA), PL 100-293". U.S. Food and Drug Administration. Archived from the original on February 23, 2008.
^ "Letter to Cephalon 01/03/2002". Food and Drug Administration. January 3, 2002. Archived from the original on April 8, 2013. Retrieved July 4, 2012.
^ Allison J (October 9, 2009). "Class Action Over Cephalon Off-Label Claims Tossed". www.law360.com. Law360. Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the FDA for distributing marketing materials that presented the drug as a remedy for tiredness, "decreased activity" and other supposed ailments. In 2008, Cephalon paid $425m and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs.
^ Zieger A (September 30, 2008). "Cephalon settlement requires physician payments to be disclosed". Fierce Healthcare. Archived from the original on May 24, 2013. Retrieved June 7, 2012.
^ "Lääkealan turvallisuus- ja kehittämiskeskuksen päätöslääkeluettelosta". Finlex.fi. 2009.
^ "Bekendtgørelse om euforiserende stoffer" [Narcotics act]. Retsinformation.dk (in Danish). June 23, 2020.
^ "Estupefacientes y Psicotrópicos" [Narcotic Drugs and Psychotropic Substances] (in Spanish). Federal Commission for Protection against Health Risks. Archived from the original on July 13, 2007. Retrieved July 21, 2007.
^ SA Government (April 10, 2003). "GENERAL REGULATIONS MADE IN TERMS OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965, AS AMENDED Government Notice R510 in Government Gazette 24727 dated 10 April 2003. 22A/16/b; states that although import and export is restricted, possession is not illegal providing that a prescription is present" (PDF). Pretoria: SAFLII. Archived from the original (PDF) on April 22, 2016. Retrieved November 11, 2016.
^ MHRA (April 3, 2013). "MHRA license for Modafinil in UK" (PDF). London: MHRA. Retrieved April 3, 2013.
^ World Anti-Doping Agency (September 5, 2017). "Prohibited List 2018" (PDF). The World Anti-Doping Code: International Standard.
^ "Clinger given lifetime ban for second doping infraction". Cycling News. August 14, 2011. Retrieved October 8, 2014.
^ "Taurasi tested positive for modafinil". The Washington Post. December 25, 2010. Retrieved December 31, 2013.
^ Guardian Sport (November 23, 2015). "British rowers handed two-year bans for taking banned substances". The Guardian.
^ Voepel M (February 18, 2011). "Taurasi: 'I've lost 3 months of my career'".
^ "Bonds Exposed". Sports Illustrated. March 7, 2006. Archived from the original on January 22, 2012. Retrieved July 2, 2011.
^ Jacobs I, Bell DG (June 2004). "Effects of acute modafinil ingestion on exercise time to exhaustion". Medicine and Science in Sports and Exercise. 36 (6): 1078–1082. doi:10.1249/01.MSS.0000128146.12004.4F. PMID 15179180. S2CID 25400053.
^ Jump up to:a b Chang CM, Sato S, Han C (May 2013). "Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression". CNS Drugs. 27 (Suppl 1): S21–S27. doi:10.1007/s40263-012-0030-1. PMID 23712796. S2CID 11869030.
^ Jump up to:a b Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (November 2013). "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials". The Journal of Clinical Psychiatry. 74 (11): 1101–1107. doi:10.4088/JCP.13r08560. PMID 24330897.
^ Jump up to:a b Abbasowa L, Kessing LV, Vinberg M (December 2013). "Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials". Nordic Journal of Psychiatry. 67 (6): 369–382. doi:10.3109/08039488.2012.752035. PMID 23293898. S2CID 25798623.
^ Jump up to:a b c Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". The Journal of Clinical Psychiatry. 75 (9): 1010–1018. doi:10.4088/JCP.13r08851. PMID 25295426.
^ Jump up to:a b Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, et al. (March 2016). "Stimulants for depression: On the up and up?". The Australian and New Zealand Journal of Psychiatry. 50 (3): 203–207. doi:10.1177/0004867416634208. PMID 26906078. S2CID 45341424.
^ Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". European Neuropsychopharmacology. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897. S2CID 3740987.
^ Jump up to:a b McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, et al. (August 2017). "The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 37 (4): 412–418. doi:10.1097/JCP.0000000000000723. PMID 28590365. S2CID 27622964.
^ Jump up to:a b c d e Bahji A, Mesbah-Oskui L (September 2021). "Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis". Journal of Affective Disorders. 292: 416–423. doi:10.1016/j.jad.2021.05.119. PMID 34144366.
^ Jump up to:a b Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737175.6.4.455. PMID 16623645. S2CID 24293088.
^ Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU (January 2017). "Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis". Journal of Psychiatric Research. 84: 292–300. doi:10.1016/j.jpsychires.2016.09.034. PMID 27810669.
^ Jump up to:a b c Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: Potential clinical uses and mechanisms of action" (PDF). The Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/jcp.v67n0406. PMID 16669720. S2CID 17047074. Archived from the original (PDF) on February 20, 2019.
^ Lindsay SE, Gudelsky GA, Heaton PC (October 2006). "Use of modafinil for the treatment of attention deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 40 (10): 1829–1833. doi:10.1345/aph.1H024. PMID 16954326. S2CID 37368284.
^ Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID 26693882. S2CID 33004517.
^ Jump up to:a b Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56: 14–34. doi:10.1016/j.eurpsy.2018.11.001. PMID 30453134. S2CID 53714228.
^ Martínez-Raga J, Knecht C, Cepeda S (June 2008). "Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies". Current Drug Abuse Reviews. 1 (2): 213–221. doi:10.2174/1874473710801020213. PMID 19630720.
^ Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G (2021). "Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?". Frontiers in Neuroscience. 15: 656475. doi:10.3389/fnins.2021.656475. PMC 8187604. PMID 34121988.
^ Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS (November 2010). "Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study". The Journal of Clinical Psychiatry. 71 (11): 1475–1481. doi:10.4088/jcp.09m05950gry. PMID 20816042.
^ Jump up to:a b Andrade C, Kisely S, Monteiro I, Rao S (January 2015). "Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials" (PDF). Journal of Psychiatric Research. 60: 14–21. doi:10.1016/j.jpsychires.2014.09.013. PMID 25306261.
^ Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (July 2017). "Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence". JAMA Psychiatry. 74 (7): 675–684. doi:10.1001/jamapsychiatry.2017.0624. PMC 6584320. PMID 28514486.
^ Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C (September 2020). "How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine" (PDF). European Neuropsychopharmacology. 38: 40–62. doi:10.1016/j.euroneuro.2020.07.002. PMID 32709551. S2CID 220651670.
^ Portela MA, Rubiales AS, Centeno C (June 2011). "The use of psychostimulants in cancer patients". Current Opinion in Supportive and Palliative Care. 5 (2): 164–168. doi:10.1097/SPC.0b013e3283462ff3. PMID 21532350. S2CID 39218702.
^ Mücke M, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L (May 2015). "Pharmacological treatments for fatigue associated with palliative care". The Cochrane Database of Systematic Reviews. 30 (5): CD006788. doi:10.1002/14651858.CD006788.pub3. PMC 6483317. PMID 26026155.
^ Kraft GH, Bowen J (December 2005). "Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study". Neurology. 65 (12): 1995–1997. doi:10.1212/01.wnl.0000200985.04239.53. PMID 16380634. S2CID 46704293.
^ Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. (January 2021). "Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial". The Lancet. Neurology. 20 (1): 38–48. doi:10.1016/S1474-4422(20)30354-9. PMC 7772747. PMID 33242419.
^ Kim H, Ayele GM, Atalay RT, Hussien S, Tewoldemedhin B, Michael MB, Scharf SM (July 2022). "What Works for One May Not Work for Another: A New Warning for Modafinil". Cureus. 14 (7): e27287. doi:10.7759/cureus.27287. PMC 9413809. PMID 36043022
Comments